Physician profile
Jaymi Smith
NPI 1992108773
$518.91
in general payments reported to CMS, 2019-2025
16 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.40 · 2023: $149 · 2024: $184 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $115.65 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $89.87 | 2023-2024 | |
| Esperion Therapeutics, INC. | $49.42 | 2021-2024 | Nexletol |
| Exact Sciences Corporation | $46.35 | 2025 | The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $30.00 | 2023 | Andexxa |
| Halozyme INC | $27.04 | 2023 | |
| Philips North America LLC | $22.75 | 2025 | Vest Therapy Und |
| Novo Nordisk INC | $19.19 | 2025 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $17.28 | 2023 | Vpriv |
| Dexcom, INC. | $17.17 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $15.26 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $14.42 | 2024 | Repatha, Otezla |
| Verona Pharma, INC. | $14.12 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $13.93 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $13.29 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $13.17 | 2023 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaymi Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.